Global Inherited Retinal Disease Market

Global Inherited Retinal Disease Market

Global Inherited Retinal Diseases market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Inherited retinal diseases is caused due to defects in the genes, that lead to vision loss and permanent blindness. More than 270 genes are responsible for this inherited disease. The defective gene alters the responsible for the structure and normal functioning of the retina.

Retinitis Pigmentosa (RP), Leber Congenital Amaurosis, and Stargardt disease are a few of the diseases that come under the inherited group of diseases. Currently, there is only one FDA-approved gene therapy as the treatment for inherited retinal diseases.

Market Dynamics: Drivers & Restraints

Increasing clinical trials

Increasing clinical trials are expected to drive the market in the forthcoming period due to the lack of treatment options for inherited retinal disorders and involve high-cost gene therapy to repair a particular gene. Several clinical trials are ongoing to find efficient treatments for inherited retinal disorders.

For instance, according to Clinicaltrials.gov, HuidaGene Therapeutics Co., Ltd. along with Cholgene Therapeutics, Inc. conducted phase 2 clinical trials to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in the RPE65 gene. The study start date is October 31, 2023. The estimated completion date is December 2025.

GenSight Biologics is conducting phase 2 clinical trials to evaluate the safety of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulating glasses) in subjects with non-syndromic retinitis pigmentosa. The study start date is September 26, 2018. The estimated completion date is December 2025.

High cost of treatment

The only approved therapy for treating inherited retinal disorders is gene therapy. Gene therapy is expensive due to its complicated procedure which involves the removal of defective genes and the insertion of normal genes in place of the abnormal gene. Luxturna costs $850,000, or $425,000 per eye per patient which is listed as one of the most expensive gene therapies. Owing to the above factor the market is expected to hinder in the forecast period.

Segment Analysis

The global inherited retinal diseases market is segmented based on disease type, treatment type, end user and region.

Retinitis Pigmentosa is Expected to Dominate Market

Retinitis Pigmentosa is one of the groups of rare eye diseases that targets the retina. It is an inherited degenerative disease that causes vision impairment. As there is no effective treatment, trials are on track by different companies.

In January 2024, Nanoscope Therapeutics Inc. provided a regulatory update on MCO-010 for the treatment of Retinitis Pigmentosa. MCO-010 has received both orphan drugs and fast-track designations from the FDA.

In December 2022, OCUGEN received orphan drug designation for the product OCU400 which is used for Retinitis Pigmentosa and Leber Congenital Amaurosis.

Geographical Analysis

North America is Expected to Dominate the Global Market

North America is expected to hold the highest share in the segment due to the prevalence of vision disorders. For instance, according to Prevent Blindness Organization, 2023, the prevalence rates of vision loss, eye health disorders, and blindness in the United States are on the rise.

Furthermore, according to the American Optometric Association, 2023, It is estimated that 12 million adults 40 years and older in the United States are living with uncorrectable vision loss, including more than 1 million Americans who are characterized as blind.

Market Segmentation

By Disease Type
• Retinitis Pigmentosa (RP)
• Choroideremia
• Stargardt disease
• Cone-rod dystrophy (CRD)
• Leber Congenital Amaurosis
• Others

By Treatment Type
• Gene Therapy
• Symptomatic Treatment

By End User
• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In January 2022, the launch of the Diana Davis Spencer Foundation Enhanced Translational Research Acceleration Program to find treatments and cures for blinding retinal disease.
• In June 2023, Beacon Therapeutics launched with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness.

Competitive Landscape

The major global players in the market include Novartis AG, REGENXBIO Inc, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies, ReNeuron Group plc, Ocugen Inc, PIXIUM VISION, Carl Zeiss Meditech AG, Spark Therapeutics, Inc. among others.

Why Purchase the Report?
• To visualize the global inherited retinal diseases market segmentation based on disease type, treatment type, end user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of inherited retinal diseases market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global inherited retinal diseases market report would provide approximately 58 tables, 59 figures, and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies